公开(公告)号：US10189856B2

公开(公告)日：2019-01-29

申请号：US13816020

申请日：2011-05-24

Applicant: Claudia Hirth-Dietrich ,  Peter Sandner ,  Johannes-Peter Stasch ,  Andreas Knorr ,  Georges Von Degenfeld ,  Michael Hahn ,  Markus Follmann

Inventor： Claudia Hirth-Dietrich ,  Peter Sandner ,  Johannes-Peter Stasch ,  Andreas Knorr ,  Georges Von Degenfeld ,  Michael Hahn ,  Markus Follmann

IPC: A61K31/437 ,  A61K31/197 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06 ,  C07D495/04 ,  C07D471/04 ,  A61K31/426 ,  C07C229/38 ,  C07D261/10 ,  C07D277/30 ,  C07D333/34 ,  C07D401/04 ,  C07D417/06 ,  C07D487/04

Abstract: The use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the concomitant fibrosis of internal organs.

公开(公告)号：US20140038956A1

公开(公告)日：2014-02-06

申请号：US13816020

申请日：2011-05-24

Applicant: Claudia Hirth-Dietrich ,  Peter Sandner ,  Johannes-Peter Stasch ,  Andreas Knorr ,  Georges Von Degenfeld ,  Michael Hahn ,  Markus Follmann

Inventor： Claudia Hirth-Dietrich ,  Peter Sandner ,  Johannes-Peter Stasch ,  Andreas Knorr ,  Georges Von Degenfeld ,  Michael Hahn ,  Markus Follmann

IPC: C07D495/04 ,  C07C229/38 ,  C07D333/34 ,  C07D261/10 ,  C07D401/04 ,  C07D417/06 ,  C07D277/30 ,  C07D487/04 ,  A61K31/5377 ,  A61K31/506 ,  A61K31/197 ,  A61K31/4439 ,  A61K31/427 ,  A61K31/426 ,  A61K31/519 ,  A61K45/06 ,  C07D471/04

CPC classification number: C07D495/04 ,  A61K31/197 ,  A61K31/426 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06 ,  C07C229/38 ,  C07D261/10 ,  C07D277/30 ,  C07D333/34 ,  C07D401/04 ,  C07D417/06 ,  C07D471/04 ,  C07D487/04 ,  A61K2300/00

Abstract: The use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the concomitant fibrosis of internal organs.

Abstract translation: 单独使用sGC刺激剂，sGC激活剂或与PDE5抑制剂联合用于预防和治疗纤维化疾病，如系统性硬化症，硬皮病和伴随的内脏纤维化。

公开(公告)号：US20130210797A1

公开(公告)日：2013-08-15

申请号：US13819790

申请日：2011-08-29

Applicant: Jürgen Klar ,  Georges Von Degenfeld ,  Hans-Georg Lerchen ,  Barbara Albrecht-Küpper ,  Andreas Knorr ,  Peter Sandner ,  Daniel Meiibom

Inventor： Jürgen Klar ,  Georges Von Degenfeld ,  Hans-Georg Lerchen ,  Barbara Albrecht-Küpper ,  Andreas Knorr ,  Peter Sandner ,  Daniel Meiibom

IPC: C07D417/12 ,  A61K45/06 ,  C07D417/14 ,  A61K31/4439 ,  C07D413/12

CPC classification number: A61K31/4439 ,  A61K9/0048 ,  A61K9/08 ,  A61K38/05 ,  A61K45/06 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14

Abstract: The present invention relates to the use of selective adenosine A1 agonists, in particular the dicyanopyridines of formula (I), for the treatment and/or prophylaxis of glaucoma and ocular hypertension as well as the their use for the production of a medicament for the treatment and/or prophylaxis of glaucoma and ocular hypertension.

公开(公告)号：US08304406B2

公开(公告)日：2012-11-06

申请号：US12297217

申请日：2007-04-03

Applicant: Martina Klein ,  Peter Sandner ,  Reiner Frey ,  Bernd Riedl ,  Olaf Christensen

Inventor： Martina Klein ,  Peter Sandner ,  Reiner Frey ,  Bernd Riedl ,  Olaf Christensen

IPC: A01N43/00 ,  A01N43/64 ,  A01N43/42 ,  A61K31/33 ,  A61K31/53 ,  A61K31/47

CPC classification number: A61K45/06 ,  A61K31/435 ,  A61K31/50 ,  Y02A50/423 ,  A61K2300/00

Abstract: The present invention relates to pharmaceutical compositions and combinations for treating, preventing or managing pulmonary hypertension comprising small molecule heterocyclic pharmaceuticals, and more particularly, substituted pyridines and pyridazines optionally combined with at least one additional therapeutic agent.

Abstract translation: 本发明涉及用于治疗，预防或控制包含小分子杂环药物的肺动脉高压的药物组合物和组合，更具体地，涉及任选与至少一种另外的治疗剂组合的取代的吡啶和哒嗪。

公开(公告)号：US20100113452A1

公开(公告)日：2010-05-06

申请号：US12297217

申请日：2007-04-03

Applicant: Martina Klein ,  Peter Sandner ,  Reiner Frey ,  Bernd Riedl ,  Olaf Christensen

Inventor： Martina Klein ,  Peter Sandner ,  Reiner Frey ,  Bernd Riedl ,  Olaf Christensen

IPC: A61K31/5025 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/501 ,  A61K31/53 ,  A61P15/10 ,  A61P9/12 ,  A61K31/506

CPC classification number: A61K45/06 ,  A61K31/435 ,  A61K31/50 ,  Y02A50/423 ,  A61K2300/00

Abstract: The present invention relates to pharmaceutical compositions and combinations for treating, preventing or managing pulmonary hypertension comprising small molecule heterocyclic pharmaceuticals, and more particularly, substituted pyridines and pyridazines optionally combined with at least one additional therapeutic agent.

Abstract translation: 本发明涉及用于治疗，预防或控制包含小分子杂环药物的肺动脉高压的药物组合物和组合，更具体地，涉及任选与至少一种另外的治疗剂组合的取代的吡啶和哒嗪。

公开(公告)号：US20120022028A1

公开(公告)日：2012-01-26

申请号：US13144929

申请日：2010-01-07

Applicant: Peter Sandner ,  Johannes-Peter Stasch ,  Michael-Friedrich Böttcher

Inventor： Peter Sandner ,  Johannes-Peter Stasch ,  Michael-Friedrich Böttcher

IPC: A61K31/635 ,  A61K31/53 ,  A61P15/10 ,  A61K31/519 ,  A61K31/4985 ,  A61K31/5377 ,  A61K31/506

CPC classification number: A61K31/53 ,  A61K31/195 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to soluble guanylate cyclase (sGC) and to phosphodiesterases (PDEs) and the pharmacology of sGC stimulators, sGC activators and PDE inhibitors. More particularly, the invention relates to the use of sGC stimulators and sGC activators in combination with PDE5 inhibitors for preparation of medicaments for the treatment of male erectile dysfunction (MED) in particular for the MED treatment of difficult to treat patients and patients not or not fully responding to PDE5 inhibitors.

Abstract translation: 本发明涉及可溶性鸟苷酸环化酶（sGC）和磷酸二酯酶（PDEs）以及sGC刺激剂，sGC激活剂和PDE抑制剂的药理学。 更具体地，本发明涉及sGC刺激剂和sGC激活剂与PDE5抑制剂组合用于制备用于治疗男性勃起功能障碍（MED）的药物的用途，特别是用于难以治疗的患者和患者的MED治疗 完全响应PDE5抑制剂。

公开(公告)号：US20110092500A1

公开(公告)日：2011-04-21

申请号：US12992083

申请日：2009-04-28

Applicant: Peter Sandner ,  Johannes-Peter Stasch

Inventor： Peter Sandner ,  Johannes-Peter Stasch

IPC: A61K31/5377 ,  A61K31/506 ,  A61K31/195 ,  A61P27/16

CPC classification number: A61K31/506 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention provides pharmacological compositions comprising a stimulator or activator of the soluble guanylate cyclase (sGC) either alone or in combination for the treatment of hearing impairment i.e. hearing loss and tinnitus.

Abstract translation: 本发明提供包含可溶性鸟苷酸环化酶（sGC）的刺激剂或活化剂的药物组合物，其单独或组合用于治疗听力损伤，即听力损失和耳鸣。

公开(公告)号：US20100210643A1

公开(公告)日：2010-08-19

申请号：US12599695

申请日：2008-04-29

Applicant: Peter Sandner ,  Hanna Tinel ,  Johannes-Peter Stasch ,  Dieter Neuser

Inventor： Peter Sandner ,  Hanna Tinel ,  Johannes-Peter Stasch ,  Dieter Neuser

IPC: A61K31/5377 ,  A61K31/505 ,  A61K31/216 ,  A61K31/53 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/506 ,  C07D403/14 ,  C07C229/38 ,  A61P13/00 ,  A61P13/10 ,  A61P13/02

CPC classification number: A61K31/506 ,  A61K31/194 ,  A61K31/519 ,  A61K31/53 ,  A61K2300/00

Abstract: The invention provides pharmacological compositions comprising a stimulator or activator of the soluble guanylate cyclase alone (sGC) or in combination with a PDE5 inhibitor for the treatment of urological disorders comprising of Benign Prostate Syndrome (BPS), Benign Prostate Hyperplasia (BPH), Benign Prostate Enlargement (BPE), Bladder Outlet Obstruction (BOO), Lower Urinary Tract Symptoms (LUTS), genitourinary disorders comprising neurogenic bladder syndrome (OAB) and (IC), urinary incontinence (UI) like mixed-, urge-, stress-, or overflow incontinence (MUI, UUI, SUI, OUI) and pelvic pain (PP).

Abstract translation: 本发明提供药物组合物，其包含单独的可溶性鸟苷酸环化酶（sGC）的刺激剂或活化剂或与PDE5抑制剂组合用于治疗泌尿系统疾病，其包括良性前列腺综合征（BPS），良性前列腺增生症（BPH），良性前列腺 包括神经源性膀胱综合征（OAB）和（IC）在内的泌尿生殖系统疾病，尿失禁（UI），如混合型，呼吸型，应激型或 溢流失禁（MUI，UUI，SUI，OUI）和盆腔疼痛（PP）。

公开(公告)号：US20090176791A1

公开(公告)日：2009-07-09

申请号：US12084659

申请日：2006-10-30

Applicant: Peter Sandner ,  Hanna Tinel ,  Joachim Hütter ,  Bernd Riedl ,  Martina Klein

Inventor： Peter Sandner ,  Hanna Tinel ,  Joachim Hütter ,  Bernd Riedl ,  Martina Klein

IPC: A61K31/4985 ,  A61K31/44 ,  A61K31/497

CPC classification number: A61K31/495

Abstract: The present invention relates to pharmaceutical compositions for treating, preventing or managing pulmonary hypertension comprising at least a diaryl urea compound optionally combined with at least one additional therapeutic agent. Useful combinations include e.g. BAY 43-9006 as a diaryl urea compound.

Abstract translation: 本发明涉及用于治疗，预防或控制肺动脉高压的药物组合物，其包含任选与至少一种另外的治疗剂组合的至少二芳基脲化合物。 有用的组合包括例如 BAY 43-9006作为二芳基脲化合物。

公开(公告)号：US20050222247A1

公开(公告)日：2005-10-06

申请号：US10996230

申请日：2004-11-23

Applicant: Stephen Boyer ,  Kentaro Hashimoto ,  Thomas Rolle ,  Peter Sandner ,  Beatrix Stelte-Ludwig ,  Hanna Tinel ,  Kerstin Henninger ,  Arnel Concepcion ,  Osamu Sakurai ,  Kanako Hirai ,  Tadashi Inoue ,  Yuki Mochizuki ,  Noriko Nunami ,  Masaomi Tajimi ,  Noriyuki Yamamoto ,  Yasuhiro Tsukimi

Inventor： Stephen Boyer ,  Kentaro Hashimoto ,  Thomas Rolle ,  Peter Sandner ,  Beatrix Stelte-Ludwig ,  Hanna Tinel ,  Kerstin Henninger ,  Arnel Concepcion ,  Osamu Sakurai ,  Kanako Hirai ,  Tadashi Inoue ,  Yuki Mochizuki ,  Noriko Nunami ,  Masaomi Tajimi ,  Noriyuki Yamamoto ,  Yasuhiro Tsukimi

IPC: A61K31/353 ,  A61K31/403 ,  A61K31/4192 ,  C07D311/58 ,  C07D405/12 ,  C07D311/74

CPC classification number: C07D311/58 ,  C07D405/12

Abstract: This invention relates to chroman derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The chroman derivatives of the present invention have an excellent activity as BETA 3 antagonists and are useful for the prophylaxis and treatment of diseases associated with BETA 3 activity, in particular for the treatment of urological disorder or disease, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor oeractivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; and inflammatory disorders, such as asthma and COPD.

Abstract translation: 本发明涉及可用作药物制剂的活性成分的苯并二氢吡喃衍生物及其盐。 本发明的苯并二氢吡喃衍生物作为BETA 3拮抗剂具有优异的活性，可用于预防和治疗与BETA 3活性相关的疾病，特别是用于治疗泌尿系统疾病或疾病，如逼尿肌过度活动（膀胱过度活动症） ，尿失禁，神经源性逼尿肌反应性（逼尿肌hyperflexia），特发性逼尿肌过度活动（逼尿肌不稳定），良性前列腺增生和下尿路症状; 和炎症性疾病，如哮喘和COPD。